By Dr. Sherrill Sellman
There has been much ado in the press recently about the wonders of the
drug tamoxifen (nolvadex). It has been heralded as a major breakthrough
in the treatment and possible prevention of breast cancer. Tamoxifen is
now the number one recommended drug treatment for women recovering from
breast cancer. With half a billion dollars (US) in annual revenues, it
is currently used by more women with breast cancer than any other prescription drug.
But as is the case with all pharmaceutical drugs, there are serious dangers
which seem to be conveniently glossed over. Far from the savior of women’s
lives, it has potential lethal side-effects.
Despite tamoxifen’s supposed ability to reduce recurrence in postmenopausal
women, major studies have shown that tamoxifen reduces death from breast
cancer only marginally. The majority of women who take tamoxifen live
no longer than women who refuse it. It is with great alarm that researchers
are finding that some breast cancers actually learn how to use tamoxifen
to stimulate their growth.
While the initial findings of tamoxifen’s role in breast cancer treatment
seemed so promising, further research presented grave concerns for its
widespread use. In fact the Physicians Desk Reference lists 25 adverse
reactions to tamoxifen. Some can be fatal.
Tamoxifen often induces menopausal symptoms in young women. About half
of the women experience hot flashes, fluid retention, weight gain, vaginal
discharge, and vaginal atrophy. Some studies have also found that premenopausal
users are at risk of developing accelerated bone mineral loss and osteoporosis.
Menstrual irregularities also occur in premenopausal women. Amenorrhea
(absence of the menstrual cycle) often results and can be permanent.
Women using tamoxifen have experienced damaged retinas, increased corneal
opacities, and decreased visual acuity. Irreversible corneal and retinal
changes can also occur. These changes may predispose the eyes to later
problems including cataracts.
Tamoxifen irritates the walls of the veins. The constant irritation and
inflammation weakens the veins causing bleeding, clotting, thrombophlebitis,
and in the worst cases — obstruction of the blood vessels serving
the lungs which can be deadly and occur with little warning. Several studies
showed that the risk of developing life-threatening blood clots increased
as much as seven times in women taking tamoxifen.
Depression has been reported as a potential side-effect of tamoxifen in
30% of women. Cases have been reported of an inability to concentrate.
Tamoxifen can trigger asthma attacks in some sensitive patients.
Vocal Cord Changes
Tamoxifen can also cause changes to the vocal cords resulting in impairment
of singing and speaking abilities.
Liver Cancer and Liver Disease
Tamoxifen is toxic to the liver and can cause acute hepatitis. The latest
human studies show a six-fold increase in liver cancer among women taking
tamoxifen for more than 2 years.9 Liver failure and tamoxifen-induced
hepatitis, although rare, have been reported. While Zeneca, the manufacturer
of tamoxifen admits that it is a liver carcinogen, it still continues
to aggressively promote its use.
Uterine (Endometrial) Cancer
Uterine growths such as polyps, tumors, endometrial thickenings and cancers
occur in a significant number of women. One study detected abnormal endometrial
cells in subjects the day after the first tablet was taken!
In a recent study, precancerous uterine and endometrial changes were seen
in 10% of the women taking tamoxifen. The higher the dose of tamoxifen,
and the longer it is taken, the greater the risk of changes. Women taking
the standard dose for two years run the risk of uterine cancer that is
2 to 3 times greater than normal. After five years the risk is 6 to 8
times greater than normal.
In February 1996 a review composed of scientists from various countries
concluded “that there is sufficient evidence to regard tamoxifen
as a human carcinogen that increases a woman’s risk of developing….
cancer of the endometrium, the inner lining of the uterus.” When
the news came out reporting that breast cancer patients who take tamoxifen
for five years or longer might have triple the risk of uterine cancer13,
many researcher said that “it’s no big deal” since early
detection of endometrial cancer rarely results in death. That statement
infuriated critics who noted that the treatment for uterine cancer is
a hysterectomy. However, now it is known that breast cancer patients who
develop uterine cancer while using tamoxifen are likely to have a fast
moving, lethal form of the disease.
In September 2000, The Lancet reported a study which showed that the drug
tamoxifen, often used to treat breast cancer and as a preventive in some
high risk women as well, increased the risk of developing endometrial
cancer. In addition, this risk increased with time, leading researchers
to question the use of the drug in healthy women. It found that women
who took tamoxifen for 2 to 5 years had twice the risk of the cancer as
women who have not taken it. Women who had taken it for 5 years or more
have a seven times higher risk of endometrial cancer. The total increased
risk for all women who used tamoxifen at all was 50%. Advanced endometrial
cancers were more common in women who had taken tamoxifen long-term than
in those who had not. The 3-year survival for endometrial cancer was “significantly
worse” for long-term tamoxifen users.
Dr. Sherrill Sellman holds a Doctorate of Naturopathy and a Bachelor of
Arts Degree (magna cum laude) – Sociology and Psychology. She is
an internationally acclaimed lecturer and best selling author of “Hormone Heresy” and “What Women MUST Know To Protect Their Daughters From Breast Cancer.” She can be contacted at